No Data
No Data
No Data
No Data
No Data
HC Wainwright & Co. Reiterates Buy on AEON Biopharma, Maintains $18 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates AEON Biopharma (AMEX:AEON) with a Buy and maintains $18 price target.
BenzingaMay 6 18:44
AEON Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 990.91% HC Wainwright & Co. → $18 Reiterates Buy → Buy 04/17/2024 990.91% HC Wainwright & Co. →
BenzingaMay 6 18:43
Maintaining Buy on AEON Biopharma: Potential of ABP-450 Despite Phase 2 Setback
TipRanksMay 6 18:18
US Equity Markets Close Higher Friday Following Weak Jobs Report
US equity markets ended higher Friday after a weak jobs report raised bets on interest rate cuts. * Nonfarm payrolls rose by 175,000 in April, well below expectations for an increase of 240,000 jobs,
MT NewswiresMay 4 04:08
Ardelyx ARDX Earnings; AEON Biopharma AEON Phase 2 Fail
BioPharmCatalystMay 4 03:46
Sector Update: Health Care
Health care stocks were mixed late Friday afternoon with the NYSE Health Care Index shedding 0.2% and the Health Care Select Sector SPDR Fund (XLV) rising 0.2%. The iShares Biotechnology ETF (IBB) cli
MT NewswiresMay 4 03:35
No Data
No Data